Display options
Cite
Rokugawa T, Uehara T, Higaki Y, et al. Potential of (99m)Tc-MIBI SPECT imaging for evaluating non-alcoholic steatohepatitis induced by methionine-choline-deficient diet in mice. EJNMMI Res. 2014;4(1):57doi: 10.1186/s13550-014-0057-z.
Rokugawa, T., Uehara, T., Higaki, Y., Matsushima, S., Obata, A., Arano, Y., & Abe, K. (2014). Potential of (99m)Tc-MIBI SPECT imaging for evaluating non-alcoholic steatohepatitis induced by methionine-choline-deficient diet in mice. EJNMMI research, 4(1), 57. https://doi.org/10.1186/s13550-014-0057-z
Rokugawa, Takemi, et al. "Potential of (99m)Tc-MIBI SPECT imaging for evaluating non-alcoholic steatohepatitis induced by methionine-choline-deficient diet in mice." EJNMMI research vol. 4,1 (2014): 57. doi: https://doi.org/10.1186/s13550-014-0057-z
Rokugawa T, Uehara T, Higaki Y, Matsushima S, Obata A, Arano Y, Abe K. Potential of (99m)Tc-MIBI SPECT imaging for evaluating non-alcoholic steatohepatitis induced by methionine-choline-deficient diet in mice. EJNMMI Res. 2014 Dec;4(1):57. doi: 10.1186/s13550-014-0057-z. Epub 2014 Oct 09. PMID: 26116119; PMCID: PMC4452628.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2014 Dec;4(1):57. doi: 10.1186/s13550-014-0057-z. Epub 2014 Oct 09.

Potential of (99m)Tc-MIBI SPECT imaging for evaluating non-alcoholic steatohepatitis induced by methionine-choline-deficient diet in mice.

EJNMMI research

Takemi Rokugawa, Tomoya Uehara, Yusuke Higaki, Shuuichi Matsushima, Atsushi Obata, Yasushi Arano, Kohji Abe

Affiliations

  1. Department of Drug Metabolism and Pharmacokinetics, Research Laboratory for Development, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka, Osaka, 561-0825, Japan, [email protected].

PMID: 26116119 PMCID: PMC4452628 DOI: 10.1186/s13550-014-0057-z

Abstract

BACKGROUND: Hepatic mitochondrial dysfunction has been implicated in pathological conditions leading to non-alcoholic steatohepatitis (NASH). Technetium-99 m-2-methoxyisobutyl-isonitrile ((99m)Tc-MIBI), a lipophilic cationic myocardial perfusion agent, is retained in the mitochondria depending on membrane potential. The aim of this study was to investigate the feasibility of (99m)Tc-MIBI for evaluating the hepatic mitochondrial dysfunction induced by methionine-choline-deficient (MCD) diet in mice.

METHODS: Male C57Black6J/jcl mice were fed a MCD diet for up to 4 weeks. SPECT scan (N =6) with (99m)Tc-MIBI was performed at 2 and 4 weeks after MCD diet. Mice were imaged with small-animal SPECT/CT under isoflurane anesthesia. Radioactivity concentrations of the liver were measured, and the time of maximum (T max) and the elimination half-life (T 1/2) were evaluated. After SPECT scan, liver histopathology was analyzed to evaluate steatosis and inflammation. Non-alcoholic fatty liver disease (NAFLD) activity score was obtained from the histological score of hepatic steatosis and inflammation. Blood biochemistry and hepatic ATP content were also measured (N =5 to 6).

RESULTS: Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were significantly elevated at 2 and 4 weeks after MCD diet. A decrease in hepatic ATP content was also observed in MCD-fed mice. (99m)Tc-MIBI SPECT imaging clearly showed the decrease of hepatic (99m)Tc-MIBI retention in MCD-fed mice compared to control mice. T 1/2 after (99m)Tc-MIBI injection was significantly decreased in the liver of MCD-fed mice (control, MCD 2 weeks, and MCD 4 weeks, T 1/2 = 57.6, 37.6, and 19.8 min, respectively), although no change in T max was observed in MCD-fed mice. SPECT data and histological score showed that the negative correlation (r = -0.74, p <0.05) between T 1/2 and NAFLD activity score was significant.

CONCLUSIONS: Hepatic (99m)Tc-MIBI elimination was increased with increase in NAFLD activity score (NAS) in mice fed MCD diet for 2 and 4 weeks. These results suggest that (99m)Tc-MIBI SPECT imaging might be useful for detecting hepatic mitochondrial dysfunction induced by steatosis and inflammation such as NAFLD or NASH.

References

  1. Carcinogenesis. 2000 May;21(5):983-9 - PubMed
  2. Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1095-105 - PubMed
  3. Mol Aspects Med. 2008 Feb-Apr;29(1-2):22-35 - PubMed
  4. Ann N Y Acad Sci. 2005 May;1042:76-81 - PubMed
  5. Free Radic Biol Med. 2014 Feb;67:330-41 - PubMed
  6. Biochem Biophys Res Commun. 1999 Apr 21;257(3):746-52 - PubMed
  7. JAMA. 1999 Nov 3;282(17):1659-64 - PubMed
  8. Eur J Nucl Med Mol Imaging. 2006 Oct;33(10 ):1107-14 - PubMed
  9. Hepatology. 2011 Oct;54(4):1208-16 - PubMed
  10. J Am Coll Cardiol. 2013 May 14;61(19):2018-9 - PubMed
  11. J Pharmacol Exp Ther. 1999 Jul;290(1):153-7 - PubMed
  12. N Engl J Med. 2002 Apr 18;346(16):1221-31 - PubMed
  13. Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1070-7 - PubMed
  14. Mitochondrion. 2007 Feb-Apr;7(1-2):164-70 - PubMed
  15. Eur Heart J. 2009 Aug;30(15):1853-62 - PubMed
  16. Hepatology. 1998 Jun;27(6):1463-6 - PubMed
  17. J Nucl Cardiol. 2010 Oct;17(5):858-67 - PubMed
  18. Pharm Res. 2010 Sep;27(9):1987-98 - PubMed
  19. J Hepatol. 2005 Jun;42(6):928-40 - PubMed
  20. Hepatol Res. 2012 Mar;42(3):273-9 - PubMed
  21. Invest Radiol. 2007 Apr;42(4):242-7 - PubMed
  22. Eur J Clin Invest. 2008 Apr;38(4):245-52 - PubMed
  23. J Hepatol. 1999 Sep;31(3):430-4 - PubMed
  24. J Clin Biochem Nutr. 2009 Nov;45(3):322-8 - PubMed
  25. Arch Biochem Biophys. 2000 Jun 15;378(2):259-68 - PubMed
  26. Hepatology. 2003 Oct;38(4):999-1007 - PubMed
  27. Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E110-9 - PubMed
  28. Int J Nucl Med Biol. 1984;11(3-4):225-34 - PubMed
  29. Eur J Radiol. 2010 Jan;73(1):137-42 - PubMed
  30. J Nucl Med. 1990 Oct;31(10):1646-53 - PubMed
  31. Drug Metab Dispos. 2014 Apr;42(4):586-95 - PubMed
  32. Eur J Nucl Med. 1993 Jan;20(1):20-5 - PubMed
  33. J Nucl Cardiol. 2007 Apr;14 (2):215-20 - PubMed

Publication Types